Semaglutide and tirzepatide show health benefits but face affordability challenges at scale
Despite proven health benefits, semaglutide and tirzepatide remain unaffordable at scale, with fewer than 1% of eligible Americans able to access current-priced drugs before budget thresholds are exceeded.
Objective Facts
The Institute for Clinical and Economic Review released a Draft Evidence Report evaluating the comparative clinical effectiveness and value of Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) for obesity management, finding that both agents produced significant weight loss and improvements in obesity-related comorbidities. While the drugs are cost-effective by conventional standards, fewer than 1% of eligible adults in the United States could be treated before surpassing ICER's budget impact threshold of $880 million annually at current net prices of $6,830 for semaglutide and $7,973 for tirzepatide. An economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. In response, President Trump announced November 2025 agreements with Eli Lilly and Novo Nordisk resulting in Most-Favored-Nation prices, with Medicare and Medicaid paying $245 per month and beneficiaries paying a $50 copay.
Left-Leaning Perspective
Progressive policy analysts from organizations like the Initiative for Medicines, Access and Knowledge (I-MAK) argue the rise of GLP-1 products demonstrates how pharmaceutical financialization perpetuates health inequities, calling for systemic reforms to the patent system to counter patent abuse and promote affordable access. Health equity advocates recommend recognizing obesity as a disease across Medicare, Medicaid and private insurers, and including semaglutide and tirzepatide in the 2027 drug-price negotiation framework to reduce out-of-pocket costs for millions of beneficiaries. Research published in JAMA Network Open noted by progressive commentators found disparities in access to semaglutide based on insurance plan type and job industry, with individuals in financial and real estate sectors far more likely to obtain prescriptions than those in retail, exemplifying how affordability barriers worsen health equity.
Right-Leaning Perspective
The Trump administration highlighted its approach through President Trump touting investments announced by Eli Lilly ($27 billion) and Novo Nordisk ($10 billion in additional domestic manufacturing commitments) as evidence that market incentives drive both pricing improvements and manufacturing expansion. Conservative policy analysts emphasize that the administration's GLP-1 pricing agreements advance a broader campaign through voluntary, most-favored-nation-style pricing, reflecting the Trump administration's preference for public-private collaboration over statutory price controls mandated by law. Right-leaning analysts acknowledge debates over compounded GLP-1s reflect legitimate tension between incentives for drug innovation and patient access questions, arguing the traditional pharmaceutical R&D model's market exclusivity periods are necessary to incentivize investment in breakthrough therapies.
Deep Dive
The immediate context involves ICER's September 2025 Draft Evidence Report on semaglutide and tirzepatide, finding both drugs produced significant weight loss and improvements in obesity-related comorbidities, but with fewer than 1% of eligible adults able to be treated at current net prices before exceeding an $880 million annual budget threshold. A parallel March 2025 economic evaluation in JAMA Health Forum found that although tirzepatide and semaglutide offered substantial long-term health benefits with QALY gains of 0.35 and 0.25 respectively, they required price reductions of 30.5% and 81.9% respectively to meet the conventional $100,000/QALY cost-effectiveness threshold. Left-leaning analysis frames the affordability crisis as resulting from pharmaceutical financialization, with Novo Nordisk filing 320 U.S. patent applications and being granted 154 patents for semaglutide, where the majority of patents relate to follow-on patents for minor modifications extending patent protection far beyond the original term, with extended patent protection increasing potential to lengthen market monopoly. Conversely, the Trump administration emphasized a market-based approach through November 2025 Most-Favored-Nation pricing agreements with Eli Lilly and Novo Nordisk, with manufacturers announcing $27 billion and $10 billion investment commitments respectively as evidence voluntary collaboration drives both affordability and innovation incentives. What each perspective overlooks: Left-leaning coverage emphasizes structural inequities in access but gives less attention to the genuine innovation incentives patent protection has historically provided for breakthrough therapies. Right-leaning emphasis on market solutions and voluntary negotiation downplays concerns that insurers may respond to lower negotiated prices by increasing prior authorization and other restrictions, as Penn LDI research documented, potentially maintaining affordability barriers even with lower net prices. Looking ahead, semaglutide is likely to be selected for Medicare price negotiation as early as 2027 under the Inflation Reduction Act, which could significantly affect future prices of antiobesity medications. Additionally, semaglutide's patent will expire in several countries starting in 2026, including India and China, with generic-drug makers poised to flood these markets with inexpensive products as industry experts predict semaglutide drugs will become cheaper and more accessible for patients with diabetes and obesity. The GLP-1 field is rapidly evolving with new benefits emerging monthly for fatty liver disease, addiction and sleep apnea, suggesting future studies may show greater long-term returns potentially tipping balance toward cost-effectiveness.